A Phase 4 interventional study of Dexamethasone and Dexmedetomidine in Breast Cancer, sponsored by Al-Azhar University. Not yet recruiting. Open to female participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Al-Azhar University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing dexamethasone in Breast Neoplasms — 5 open to participants now, 5 under way, 1 of them phase 3. Dexamethasone · Breast Neoplasms.
Among the 14 studies testing dexamethasone in Breast Neoplasms, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is one of 3 in phase 4, and was the 10th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 14 studies testing dexamethasone in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Brown University · Sites in United States
Ages 18+
Mario Negri Institute for Pharmacological Research
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
The Netherlands Cancer Institute
Ages 18+ · Women only
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 20 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 80 across the 14 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Al-Azhar University is the lead sponsor of 536 studies on the registry; 172 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Al-Azhar University has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing dexamethasone in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974604Brown UniversityPreventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing dexamethasone in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Modified radical mastectomy is the most commonly performed surgical approach for breast cancer. The procedure enables surgeons to remove the main tumor mass, adjacent glandular tissue and regional lymph nodes. Moreover, it provides a cosmetic outcome that clearly surpasses the standard radical mastectomy and allows subsequent breast reconstruction with favorable results.
The present randomized study aims to compare the postoperative analgesic effects of dexamethasone and dexmedetomidine as adjuncts to serratus anterior plane block in women undergoing modified radical mastectomy.
Modified radical mastectomy is the most commonly performed surgical approach for breast cancer. The procedure enables surgeons to remove the main tumor mass, adjacent glandular tissue and regional lymph nodes. Moreover, it provides a cosmetic outcome that clearly surpasses the standard radical mastectomy and allows subsequent breast reconstruction with favorable results.
Serratus anterior plane block (SAPB) with ultrasound guidance is a fascial plane block that proved to be feasible, safe and effective tool for reduction of postoperative pain after thoracic and breast surgeries. In multiple instances, SAPB is used with additional adjuncts e.g. dexamethasone or dexmedetomidine to improve analgesic potency and duration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Consecutive (ASA) class I-II female patients with breast cancer indicated for modified radical mastectomy
Exclusion Criteria:
Allergy to the study medications . Patients will also be excluded if they have history of chronic pain conditions, opioid dependence or if they received prolonged analgesic therapy prior to surgery.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexamethasone injection
Drug: Dexamethasone
Dexmedetomidine injection.
Drug: Dexmedetomidine
Dexamethasone as adjunct to serratus anterior plane block.
Dexmedetomidine as adjunct to serratus anterior plane block.
postoperative visual assessment scale for pain.
Subjective pain assessment scale
Time frame: 72 hours postoperative
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2024; primary completion for Oct 2024, 6 months later.
Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 6 months is below that.
Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Dexmedetomidine